Melanoma and cannabinoids: A possible chance for cancer treatment.
angiogenesis
cancer progression
cannabinoids
invasion
melanoma
proliferation
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
04
07
2024
received:
23
11
2023
accepted:
10
07
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
ppublish
Résumé
The endocannabinoid system is composed by a complex and ubiquitous network of endogenous lipid ligands, enzymes for their synthesis and degradation, and receptors, which can also be stimulated by exogenous compounds, such as those derived from the Cannabis sativa. Cannabis and its bioactive compounds, including cannabinoids and non-cannabinoids, have been extensively studied in different conditions. Recent data have shown that the endocannabinoid system is responsible for maintaining the homeostasis of various skin functions such as proliferation, differentiation and release of inflammatory mediators. Because of their role in regulating these key processes, cannabinoids have been studied for the treatment of skin cancers and melanoma; their anti-tumour effects regulate skin cancer progression and are mainly related to the inhibition of tumour growth, proliferation, invasion and angiogenesis, through apoptosis and autophagy induction. This review aims at summarising the current field of research on the potential uses of cannabinoids in the melanoma field.
Substances chimiques
Cannabinoids
0
Endocannabinoids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15144Informations de copyright
© 2024 The Author(s). Experimental Dermatology published by John Wiley & Sons Ltd.
Références
Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst. 1975;68(3):597‐602.
Console‐Bram L, Marcu J, Abood ME. Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuro‐Psychopharmacol Biol Psychiatry. 2012;38(1):4‐15.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561‐564.
Munro S, Thomas KL, Abu‐Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61‐65.
Hillard CJ. Circulating endocannabinoids: from whence do they come and where are they going? Neuropsychopharmacology. 2018;56:155‐172.
Hinz B, Ramer R. Anti‐tumour actions of cannabinoids. Br J Pharmacol. 2019;176:1384‐1394.
Laezza C, Pagano C, Navarra G, et al. The endocannabinoid system: a target for cancer treatment. Int J Mol Sci. 2020;21(3):747.
Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 2006;46:101‐122.
Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 2001;22:565‐572.
Christie MJ, Vaughan CW. Neurobiology: cannabinoids act backwards. Nature. 2001;410:527‐530.
Szabo B, Siemes S, Wallmichrath I. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci. 2002;15:2057‐2061.
Rodríguez‐Muñoz M, Sánchez‐Blázquez P, Merlos M, GarzónNiño J. Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. Oncotarget. 2016;7:55840‐55862.
Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20(Suppl 1):10‐14.
Caterina MJ. TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation. ACS Chem Neurosci. 2014;5:1107‐1116.
Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389‐462.
Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. 2009;30:411‐420.
Basu S, Dittel BN. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res. 2011;51(1):26‐38.
Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: Progress and promise. Cancer Res. 2008;68(2):339‐342.
Kupczyk P, Reich A, Szepietowski JC. Cannabinoid system in the skin – a possible target for future therapies in dermatology. Exp Dermatol. 2009;18(8):669‐679.
Rao GK, Zhang W, Kaminski NE. Cannabinoid receptor‐mediated regulation of intracellular calcium by delta(9)‐tetrahydrocannabinol in resting T cells. J Leukoc Biol. 2004;75:884‐892.
Peeri H, Koltai H. Cannabis biomolecule effects on cancer cells and cancer stem cells: cytotoxic, anti‐proliferative, and anti‐migratory activities. Biomol Ther. 2022;12(4):491.
Ye L, Cao Z, Wang W, Zhou N. New insights in cannabinoid receptor structure and signaling. Curr Mol Pharmacol. 2019;12(3):239‐248.
Galve‐Roperh I, Rueda D, Gómez del Pulgar T, Velasco G, Guzmán M. Mechanism of extracellular signal‐regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol. 2002;62(6):1385‐1392.
Alexander SPH, Benson HE, Faccenda E, et al. The concise guide to PHARMACOLOGY 2013/14: G protein‐coupled receptors. Br J Pharmacol. 2013;170:1459‐1581.
Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152:1092‐1101.
Adinolf B, Romanini A, Vanni A, et al. Anticancer activity of anandamide in human cutaneous melanoma cells. Eur J Pharmacol. 2013;718:154‐159.
De PL, Bisogno T, Maccarrone M, et al. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem. 2001;276:12856‐12863.
Ständer S, Moormann C, Schumacher M, et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol. 2004;13:129‐139.
Ahluwalia J, Urban L, Bevan S, Nagy I. Anandamide regulates neuropeptide release from capsaicin‐sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci. 2003;17:2611‐2618.
de la Harpe A, Beukes N, Frost CL. CBD activation of TRPV1 induces oxidative signaling and subsequent ER stress in breast cancer cell lines. Biotechnol Appl Biochem. 2022;69(2):420‐430.
Sertznig P, Reichrath J. Peroxisome proliferator‐activated receptors (PPARs) in dermatology: challenge and promise. Dermatoendocrinol. 2011;3(3):130‐135.
O'Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173:1899‐1910.
Gupta M, Mahajan VK, Mehta KS, Chauhan PS, Rawat R. Peroxisome proliferator‐activated receptors (PPARs) and PPAR agonists: the “future” in dermatology therapeutics? Arch Dermatol Res. 2015;307:767‐780.
Oesch S, Gertsch J. Cannabinoid receptor ligands as potential anticancer agents—high hopes for new therapies? J Pharm Pharmacol. 2009;61(7):839‐866.
Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:1‐46.
Suryavanshi SV, Koltai I, Koltai O. Cannabinoids as key regulators of inflammasome signaling: a current perspective. Front Immunol. 2021;11:1‐20.
Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: an overview. Immunobiology. 2010;215:588‐597.
Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti‐inflammatory drugs. Future Med Chem. 2009;1:1333‐1349.
Bhandaru M, Rotte A. Blockade of programmed cell death protein‐1 pathway for the treatment of melanoma. J Dermatol Res Ther. 2017;1(3):1‐11.
Bhandaru M, Rotte A. Monoclonal antibodies for the treatment of melanoma: present and future strategies. Methods Mol Biol. 2019;1904:83‐108.
Laurent S, Queirolo P, Boero S, et al. The engagement of CTLA‐4 on primary melanoma cell lines induces antibody‐dependent cellular cytotoxicity and TNF‐α production. J Transl Med. 2013;11:108.
Contardi E, Palmisano GL, Tazzari PL, et al. CTLA‐4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer. 2005;117:538‐550.
Queirolo P, Boutros A, Tanda E, Spagnolo F, Quaglino P. Immune‐checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Semin Cancer Biol. 2019;59:290‐297.
Martens A, Wistuba‐Hamprecht K, Yuan J, et al. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22:4848‐4858.
Balatoni T, Ladányi A, Fröhlich G, et al. Biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Pathol Oncol Res. 2020;26:317‐325.
Gómez del Pulgar T, Velasco G, Sánchez C, Haro A, Guzmán M. De novo‐synthesized ceramide is involved in cannabinoid‐induced apoptosis. Biochem J. 2002;363(Pt 1):183‐188.
Carracedo A, Lorente M, Egia A, et al. The stress‐regulated protein p8 mediates cannabinoid‐induced apoptosis of tumor cells. Cancer Cell. 2006;9(4):301‐312.
Herrera B, Carracedo A, Diez‐Zaera M, Gómez del Pulgar T, Guzmán M, Velasco G. The CB2 cannabinoid receptor signals apoptosis via ceramide‐dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res. 2006;312(11):2121‐2131.
McAllister SD, Abood ME, Califano J, Guzmán M. Cannabinoid cancer biology and prevention. J Natl Cancer Inst Monogr. 2021;2021(71):99‐106.
Sailler S, Schmitz K, Jäger E, et al. Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans. Onco Targets Ther. 2014;1(4):272‐282.
Zhang X, Qin Y, Pan Z, et al. Cannabidiol induces cell cycle arrest and cell apoptosis in human gastric cancer SGC‐7901 cells. Biomol Ther. 2019;9(8):302. doi:10.3390/biom9080302
Kisková T, Mungenast F, Suváková M, Jäger W, Thalhammer T. Future aspects for cannabinoids in breast cancer therapy. Int J Mol Sci. 2019;20(7):1673. doi:10.3390/ijms20071673
An D, Peigneur S, Hendrickx LA, Tytgat J. Targeting cannabinoid receptors: current status and prospects of natural products. Int J Mol Sci. 2020;21(14):5064. doi:10.3390/ijms21145064
Roberto D, Klotz LH, Venkateswaran V. Cannabinoid WIN 55,212‐2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid‐receptor 2 dependent manner. Prostate. 2019;79:151‐159. doi:10.1002/pros.23720
Hanlon KE, Lozano‐Ondoua AN, Umaretiya PJ, et al. Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH‐015, is calcium dependent. Breast Cancer (Dove Med Press). 2016;8:59‐71. doi:10.2147/BCTT.S100393
Nabissi M, Morelli MB, Offidani M, et al. Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016;7:77543‐77557. doi:10.18632/oncotarget.12574
Jeong S, Jo MJ, Yun HK, et al. Cannabidiol promotes apoptosis via regulation of XIAP/Smac in gastric cancer. Cell Death Dis. 2019;10(11):846. doi:10.1038/s41419-019-2001-7
Garcia‐Arencibia M, Molina‐Holgado E, Molina‐Holgado F. Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells. Br J Pharmacol. 2019;176(10):1361‐1369. doi:10.1111/bph.14369
Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross‐talk between apoptosis and autophagy. Mol Cancer Ther. 2011;10(7):1161‐1172. doi:10.1158/1535-7163.MCT-10-1100
Eichele K, Ramer R, Hinz B. R(+)‐Methanandamide‐induced apoptosis of human cervical carcinoma cells involves a Cyclooxygenase‐2‐dependent pathway. Pharm Res. 2009;26:346‐355. doi:10.1007/s11095-008-9748-3
Caffarel MM, Sarrió D, Palacios J, Guzmán M, Sánchez C. Delta9‐tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006;66(13):6615‐6621. doi:10.1158/0008-5472.CAN-05-4566
Soliman E, Van Dross R. Anandamide‐induced endoplasmic reticulum stress and apoptosis are mediated by oxidative stress in non‐melanoma skin cancer: receptor‐independent endocannabinoid signaling. Mol Carcinog. 2016;55(11):1807‐1821. doi:10.1002/mc.22429
Wang J, Xu Y, Zhu L, et al. Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression. J Cancer Res Clin Oncol. 2018;144:39‐52. doi:10.1007/s00432-017-2527-y
Li Pomi F, Borgia F, Custurone P, Vaccaro M, Pioggia G, Gangemi S. Role of HMGB1 in cutaneous melanoma: state of the art. Int J Mol Sci. 2022;23:9327. doi:10.3390/ijms23169327
Di Bartolomeo L, Vaccaro F, Irrera N, et al. Wnt signaling pathways: from inflammation to non‐melanoma skin cancers. Int J Mol Sci. 2023;24:1575. doi:10.3390/ijms24021575
Papa V, Li Pomi F, Borgia F, Vaccaro M, Pioggia G, Gangemi S. Immunosenescence and skin: a state of art of its etiopathogenetic role and crucial watershed for systemic implications. Int J Mol Sci. 2023;24:7956. doi:10.3390/ijms24097956
Zhao Z, Yang J, Zhao H, Fang X, Li H. Cannabinoid receptor 2 is upregulated in melanoma. J Cancer Res Ther. 2012;8(4):549‐567.
Blázquez C, Carracedo A, Barrado L, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 2006;20(14):2633‐2635. doi:10.1096/fj.06-6635fje
Simmerman E, Qin X, Yu JC, Baban B. Cannabinoids as a potential new and novel treatment for melanoma: a pilot study in a murine model. J Surg Res. 2019;235:210‐215.
Blázquez C, Casanova ML, Planas A, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 2003;17(3):529‐531. doi:10.1096/fj.02-0795fje
Haskó J, Fazakas C, Molnár J, et al. CB2 receptor activation inhibits melanoma cell transmigration through the blood–brain barrier. Int J Mol Sci. 2014;15(5):8063‐8074. doi:10.3390/ijms15058063
Kenessey I, Bánki B, Márk A, et al. Revisiting CB1 receptor as drug target in human melanoma. Pathol Oncol Res. 2012;18(4):857‐866. doi:10.1007/s12253-012-9512-0
Glodde N, Jakobs M, Bald T, Tüting T, Gaffal E. Differential role of cannabinoids in the pathogenesis of skin cancer. Life Sci. 2015;1(138):35‐53. doi:10.1016/j.lfs.2015.07.002
Qin Y, Verdegaal EM, Siderius M, et al. Quantitative expression profiling of G‐protein‐coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target. Pigment Cell Melanoma Res. 2011;24(1):207‐218. doi:10.1111/j.1755-148X.2010.00785.x
Adinolfi B, Romanini A, Vanni A, et al. Anticancer activity of anandamide in human cutaneous melanoma cells. Eur J Pharmacol. 2013;718(1–3):154‐159. doi:10.1016/j.ejphar.2013.08.024
Huang S, Yu S, Deng R, et al. TRPV4 promotes metastasis in melanoma by regulating cell motility through cytoskeletal rearrangement. Int J Mol Sci. 2022;23(23):15155. doi:10.3390/ijms232315155
Carpi S, Fogli S, Romanini A, et al. AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells. Anti‐Cancer Drugs. 2015;26(7):754‐762. doi:10.1097/CAD.0000000000000246
Scuderi MR, Cantarella G, Scollo M, et al. The antimitogenic effect of the cannabinoid receptor agonist WIN55212‐2 on human melanoma cells is mediated by the membrane lipid raft. Cancer Lett. 2011;310(2):240‐249. doi:10.1016/j.canlet.2011.07.017
Armstrong JL, Hill DS, McKee CS, et al. Exploiting cannabinoid‐induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol. 2015;135(6):1629‐1637. doi:10.1038/jid.2015.41
Levine B. Cell biology: autophagy and cancer. Nature. 2007;446(7137):745‐747. doi:10.1038/446745a
Armstrong JL, Corazzari M, Martin S, et al. Oncogenic B‐RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition. Clin Cancer Res. 2011;17(8):2216‐2226. doi:10.1158/1078-0432.CCR-10-2754
Corazzari M, Fimia GM, Lovat P, Piacentini M. Why is autophagy important for melanoma? Molecular mechanisms and therapeutic implications. Semin Cancer Biol. 2013;23(5):337‐356. doi:10.1016/j.semcancer.2013.07.002
Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D. The non‐psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci. 2006;63(17):2057‐2066. doi:10.1007/s00018-006-6240-8
Torres S, Lorente M, Rodríguez‐Fornés F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011;10(1):90‐103. doi:10.1158/1535-7163.MCT-10-0688
Gęgotek A, Biernacki M, Ambrożewicz E, Surażyński A, Wroński A, Skrzydlewska E. The cross‐talk between electrophiles, antioxidant defence and the endocannabinoid system in fibroblasts and keratinocytes after UVA and UVB irradiation. J Dermatol Sci. 2016;81(2):107‐117. doi:10.1016/j.jdermsci.2015.11.014
Souri Z, Wierenga APA, van Weeghel C, et al. Loss of BAP1 is associated with upregulation of the NFkB pathway and increased HLA class I expression in uveal melanoma. Cancers (Basel). 2019;11(8):1102. doi:10.3390/cancers11081102